UNSPSC 51273825: Guaiacol/methyl salicylate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE650. This VA Drug Class (DE650) classifies this compound as belonging to the group ANALGESICS, TOPICAL.

UNSPSC 51273825 Guaiacol/methyl salicylate is a Commodity code whose recent state and local activity shows minimal alignment with its nominal chemical product scope. The three most recent opportunities tagged to this code involve procurement of naloxone and drug deactivation systems, a request for information on direct-to-manufacturer prescription programs, and a multi-state cooperative purchasing contract for generic pharmaceuticals and OTC products — none of which are guaiacol or methyl salicylate derivatives. The code appears to capture pharmaceutical and health-product procurement at the state and local level in broader terms than its chemical name suggests, though the disconnect between the code designation and actual scope raises questions about how systematically this commodity is categorized in practice.

Recent activity spans Florida county government (Seminole County Community Health), state health agencies (Texas Health and Human Services Commission), and cooperative purchasing consortia (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon). The Seminole County IFB 60459723LAS, due July 26, 2023, sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas HHS RFI HHS0017013 (April 3, 2026) sought vendor capabilities for direct-to-manufacturer prescription programs; and the MMCAP RFP S1070000015802 (due March 26, 2026) established multi-state contracts for generic pharmaceuticals and OTC products through authorized wholesalers with a July 1, 2026 effective date. Recent procurement is concentrated in the Southeast and South (Florida, Texas) with multi-state cooperative reach, though the small sample and apparent code-scope mismatch suggest limited actionability under the guaiacol/methyl salicylate designation itself.